Evidence map›Paper›PMID 25045527›Full record

ArticleMolecular and cellular therapies2013

Recruitment and retention of human autologous CD34+ CD117+ CD133+ bone marrow stem cells to infarcted myocardium followed by directed vasculogenesis: Novel strategy for cardiac regeneration.

Marek Malecki, Chelsea Sabo, Emily Putzer, Chris Stampe, Afsoon Foorohar, Carol Quach, Michael Beauchaine, Xenia Tombokan, Mark Anderson

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Molecular and cellular therapies, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Deciphering the Cardiovascular Potential of Human CD34International journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Stimulating endogenous cardiac repair.Frontiers in cell and developmental biology · 2015
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marek MaleckiPhoenix Biomolecular Engineering Foundation, San Francisco, CA, USA ; National Magnetic Resonance Facility, National Institutes of Health ; University of Wisconsin, Madison, WI, USA.
Chelsea SaboUniversity of Wisconsin, Madison, WI, USA ; University of Sheffield, Sheffield, EU, UK.
Emily PutzerUniversity of Wisconsin, Madison, WI, USA ; American Youth Center, Washington, DC, USA.
Chris StampeUniversity of Minnesota, Minneapolis, MN, USA.
Afsoon FooroharPhoenix Biomolecular Engineering Foundation, San Francisco, CA, USA ; Western University, Lebanon, OR, USA.
Carol QuachPhoenix Biomolecular Engineering Foundation, San Francisco, CA, USA ; Western University, Pomona, CA, USA.
Michael BeauchaineAXS Bruker, Madison, WI, USA.
Xenia TombokanBioSpin Bruker, The Woodlands, TX, USA.
Mark AndersonNational Magnetic Resonance Facility, National Institutes of Health ; University of Wisconsin, Madison, WI, USA.

Funding

WATER DISTRIB:PHYSICAL PROPERT:PIZZA &LMPS MOZZARELLA CHEESES:EARLY STAGE MATURP41RR002301 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 1985 to 2011
$13.0M
XENOPUS OOCYTE NUCLEAR ENVELOPE STRUCTUREP41RR000570 · NCRR · UNIVERSITY OF WISCONSIN MADISON · 1985 to 1998
–
NCRR NIH HHS P41 RR000570NCRR NIH HHS P41 RR002301
6 · The paper itself

Abstract

backgroundOngoing clinical trials, in regenerative therapy of patients suffering from myocardial infarctions, rely primarily upon administration of bone marrow stem cells to the infarcted zones. Unfortunately, low retention of these cells, to the therapeutic delivery sites, reduces effectiveness of this strategy; thus it has been identified as the most critical problem for advancement of cardiac regenerative medicine. SPECIFIC

aimsThe specific aim of this work was three-fold: (1) to isolate highly viable populations of human, autologous CD34+, CD117+, and CD133+ bone marrow stem cells; (2) to bioengineer heterospecific, tetravalent antibodies and to use them for recruiting of the stem cells to regenerated zones of infarcted myocardium; (3) to direct vasculogenesis of the retained stem cells with the defined factors. PATIENTS

methodsCardiac tissue was biopsied from the hearts of the patients, who were receiving orthotopic heart transplants after multiple cardiac infarctions. This tissue was used to engineer fully human

resultsAdministration of the bioengineered, heterospecific antibodies preceding administration of the stem cells greatly improved the stem cells' recruitment and retention to the infarcted myocardium. Treatment of the retained stem cells with vascular endothelial growth factor and angiopoietin efficiently directed their differentiation into endothelial cells, which expressed vascular endothelial cadherin, platelet / endothelial cell adhesion molecule, claudin, and occludin, while forming tight and adherens junctions.

conclusionsThis novel strategy improved retention of the patients' autologous bone marrow stem cells to the infarcted myocardium followed by directed vasculogenesis. Therefore, it is worth pursuing it in support of the ongoing clinical trials of cardiac regenerative therapy.

Indexed as

Bone marrow stem cellsHeterospecific tetravalent antibodiesMyocardial infarctionRegenerative medicineStem cell therapyVasculogenesis

Identifiers

PMID25045527
PMCPMC4100620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.